Clinical Trial Update: Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating subacute effect of Tolvaptan on total kidney volume in adults with autosomal dominant polycystic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• tolvaptan (tolvaptan)

Snippet

Sponsor: Lisbet Brandi | Conditions: Autosomal Dominant Polycystic Kidney | Phase 4 | Status: UNKNOWN